CG Oncology 的膀胱癌免疫疗法降低肿瘤复发风险
STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence
CG Oncology 的免疫治疗药物 cretostimogene 在一项 III 期临床试验中,将膀胱癌复发风险降低了 68%,可能改变临床治疗策略。
研究结果显示免疫治疗显著降低膀胱癌复发风险,可能改变临床治疗策略。
![]()
Nov. 16, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
A cancer immunotherapy from CG Oncology delivered into the bladders of patients reduced the risk of tumor recurrence by 68% compared to current medical practice — positive study results announced Monday that may change the way physicians treat certain patients with bladder cancer.
The CG Oncology treatment, called cretostimogene, is made from a type of common cold virus engineered to target cells that express a specific mutation found in bladder tumors. Physicians use a catheter to infuse “creto” directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, then breaks open the cells, killing them.
The randomized Phase 3 study enrolled 367 patients with intermediate-risk bladder cancer, a localized form of the disease that is typically removed in a minimally invasive surgical procedure. Patients are then monitored every three months. If the cancer returns, repeat surgical procedures can be performed, but over time, patients lose bladder function and the cancer can continue to grow.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com